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Medicines: 
mere generic facts
Originator and generic medicines are often identified either by their 
generic name or their brand name. Good Manufacturing Practice 
(GMP) standards ensure that medicines are of high quality, and thus 
support policies of generic prescribing and generic substitution. 
The substitution model adopted in Malta promotes rational use 
and favours competition between different brands. Competition 
is essential for inducing innovation of medicines and for the 
sustainability of the pharmaceutical industry. The availability of 
medicines, the knowledge on these medicines and confidence in 
their use, are crucial for the rational use of medicines as well as for 
the strengthening of the medicines market.
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Introduction
All medicines which are placed on the 
market have at least three names. The 
chemical name is based on its chemical 
structure. The generic name also known 
as international non-proprietary name 
(INN), reflects the active ingredient and 
the proprietary name is usually a registered 
trademark.1,2  
An original medicinal product has a 
unique trade name for marketing purposes, 
also known as the brand name.2 On the 
market, one finds branded generics or 
unbranded generics. The branded generics 
also have a specific trade name, while 
the unbranded generics use the INN and 
the manufacturer’s name. Generic names 
indicate the medical class thus providing 
the health care professionals with the 
drug’s pharmacology and classification. 
Generic names are international. Brand 
names for the same drug may vary between 
countries.1,2 
Some doctors may be reluctant to 
prescribe the generic name while patients 
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may not accept a different brand name than 
the usual.3 The knowledge or lack of it, may 
be determining the attitude and behaviour 
of both health professionals and patients 
towards medicines, and this reflects on the 
rational or irrational use of medicines.
Originator	and	generic	medicines
The originator medicinal product is 
the first version of a pharmaceutical, 
developed and patented by an originator 
pharmaceutical company which has 
exclusive rights to marketing the product in 
the European Union (EU) for 1 years.2  
A generic medicine is a pharmaceutical 
product which is no longer protected by 
a patent and thus can be copied by other 
pharmaceutical companies and marketed 
either under its own brand or as an 
unbranded product, ideally at a cheaper 
price. These manufacturers do not face 
the risks and costs linked to the research 
and development (R&D) of innovative, 
originator medicines. The pre-clinical tests 
and clinical trials are not necessary. Instead 
bioequivalence studies are carried out. 
Thus, a company which decides to 
formulate and manufacture a generic 
medicine, has to ensure that it is 
bioequivalent to the original trade-
name drug, and that appropriate 
active ingredients are used, and that 
it is manufactured according to Good 
Manufacturing Practice (GMP) standards.,6 
Bioequivalence implies that two medicines 
are pharmaceutically equivalent and 
their bioavailability is similar to such a 
degree that their effect can be expected 
to be essentially the same.2  The inactive 
ingredients used may be different and may, 
though rarely, cause unusual reactions in 
the body. 
Since the accession of Malta in the 
EU in May of 200, the EU legislation 
with respect to medicinal products, their 
manufacture and supply, has been adopted. 
The transposition of the EU legislation 
into the national legislation – Medicines 
Act, 2003 and its subsidiary legislation 
– has provided a legal framework which 
ensures that both originator and generic 
medicines available in Malta, meet specific 
standards of quality, safety and efficacy.7,8 
This legislation deters medicinal products 
of dubious quality from reaching the market 
and boosts the confidence of healthcare 
professionals and patients in using any of 
the medicines available.
Prescribing	of	medicines
The discovery and development of 
new medicines is very costly. During the 
patented period, an innovator medicine 
is granted monopoly so that this period 
could possibly be one of high expense 
to the health service provider or the 
patient.  In this period, the product is 
marketed extensively and by the time the 
patent expires the brand name is strongly 
associated with the generic name in many 
prescribers’ minds.1 
Active, continuous encouragement 
and promotion of generic prescribing 
has been shown to increase the rate of 
generic prescribing, which in turn promotes 
competition and exerts a downward pressure 
on the prices of medicines.9 The prescription 
process could be an essential source of 
efficiency within a health care system.10 In 
Malta, doctors are trained to prescribe by 
generic name, and in the Government Health 
Services, a ‘generic prescribing policy’ is 
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in place. The procurement of medicines by 
the Government Pharmaceutical Services, is 
based on the generic name of the medicine. 
Generic prescribing facilitates substitution 
when a medicinal product with a different 
brand name is made available. 
Both the patient’s therapeutic needs 
and the financial situation determine what 
medicines a doctor prescribes.10 Generic 
prescribing may be limited by the belief 
that generic medicines are of poorer quality 
than their originator counterpart. Two 
preparations formulated by two different 
manufacturers cannot be exactly identical.1 
However, regulations regarding standards of 
manufacture and Marketing Authorisation 
ensure that they are bioequivalent and 
meet requirements of quality, safety 
and efficacy.2,6 If an originator branded 
product is more expensive than the generic 
alternative, it does not mean that the 
originator brand is of superior quality or 
efficacy, and vice-versa.1 
Substitution	of	medicines
The EU aims to make efficacious, high 
quality and safe medicines readily accessible 
to patients. Amongst its objectives, one 
finds the promotion of clinical and cost-
effective prescribing and of the wider and 
appropriate use of generic medicines.11 
Generic substitution is the practice of 
substituting a pharmaceutical, whether 
marketed under a trade name or generic 
name (branded or unbranded generic), by 
a pharmaceutical, often a cheaper one, 
containing the same active ingredient(s).2 
However, different policies and different 
models are adopted by the EU Member 
states.11 One model allows the replacement 
by the pharmacist of the prescribed branded 
drug by a generic with the same active 
ingredient, possibly without consulting 
either the patient or the doctor. Some 
argue that doctors should be able to 
prescribe branded medicines as they know 
what is best for the patient. Substitution 
may induce the prioritization of economic 
considerations over patients needs, and a 
model which supports the substitution of 
originator brand with the generic medicine 
might give generics an unfair competitive 
advantage.,11  
The generics substitution should 
promote the rational use of medicines 
so that patients receive medications 
appropriate to their clinical needs (Table 
1), in doses that meet their individual 
requirements, for an adequate period of 
time, and at the lowest cost to them and 
their community.12  
The model of medicines substitution 
adopted in Malta supports the rational 
use of medicines. In fact according to the 
current legislation,
“Upon presentation of a prescription for 
a medicinal product, unless the prescriber 
specifically requests a particular branded 
product by writing “branded” or “®” on the 
prescription, a pharmacist can dispense the 
medicinal product prescribed or an equivalent 
medicinal product having the same chemical 
entity, dose, dosage form, formulation and 
dosage frequency as the medicinal product 
indicated on the prescription.” 
(Article 80, Medicines Act, 2003).7 
Thus, in Malta the prescriber can 
prescribe a particular branded product 
where it is deemed necessary. On the other 
hand, the pharmacist may substitute the 
prescribed medicine with a less expensive 
alternative, which could be either the 
originator or a generic medicine. This model 
provides several advantages to pharmacists, 
doctors and patients. Community 
pharmacists do not need to stock several 
different brands of the same medicine as 
the pharmacist has a choice over which 
brand may be dispensed. Thus, wastage 
of money and expired medicines is less 
likely. A pharmacist may buy one brand in 
bulk thus ensuring that the generic drug is 
always available for the patients. A delay 
in the start of treatment and inconvenience 
to the patients are avoided when a generic 
equivalent to the prescribed medicine is 
available.1 Those patients who cannot 
afford certain branded medicinal products 
can be offered an alternative which aids in 
lowering their financial burden.  
Similarly to other policies which 
promote rational use, generic substitution 
can be quite controversial and thus 
may encounter opposition.13 Doctors 
and pharmacists could have a financial 
interest in prescribing or dispensing those 
medicines with the highest profit margins. 
Doctors may see generic substitution as 
an interference with their freedom to 
prescribe. The prescribing and dispensing 
of newly marketed or expensive medicines 
could be associated with a certain status.13 
Inappropriate promotion and lack of 
information for health professionals and 
consumers can result in misunderstandings 
which in turn lead to irrational use of 
medicines.
In Malta, besides the legislation 
governing the substitution of medicines, 
there are also the Advertising Regulations 
which govern the promotion of medicines.1 
These regulations help to decrease the 
influences which misleading claims and 
financial incentives may have on the 
rational prescribing, dispensing and use of 
medicines. Information on the medicines 
authorized and marketed in Malta is 
provided by the Malta Medicines List 
published on the website of the National 
Medicines Policy & Audit Unit (NMPAU) 
within the Ministry for Health, the Elderly 
and Community Care (MHEC).1 This list 
is classified by the Anatomic Therapeutic 
Chemical (ATC) code and enables the 
identification of alternatives available.  
Medicines	expenditure
The key objectives of a government’s 
medicines policy should include the 
identification of medicines that bring the 
greatest benefit to patients, ensuring early 
access to medicines and providing choice 
of high value medicines.16 Affordable 
prices are an important prerequisite for 
ensuring access to good quality essential 
medicines.13,17 Affordability depends on 
pricing policies, price negotiations and 
Table	1.	Situations	where	generic	substitution	may	not	be	appropriate1,3,5
• The medicine has a narrow therapeutic window e.g. digoxin, warfarin
• Plasma levels have to be measured and the dose of the medicine has to be carefully 
titrated against clinical effect
• The pharmaceutical preparation is a modified-release preparation
• The inhalers are CFC free
• The preparation has many active ingredients
• The patient suffers from an intolerance to an excipient
• There is an issue of patient compliance
• Patient may not be reassured and will not accept a substitute to the usual brand
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Practice	points
1. Medicines have three names: chemical name, generic name and brand name.
2. In the ATC classification system pharmaceuticals are divided into different 
groups according to the organ or system on which they act and their chemical, 
pharmacological and therapeutic properties.2  
3. In Malta, substitution of a medicinal product with an equivalent alternative can be 
done.11 
. As increasing demands are being made on healthcare services, generic medicines 
provide a major benefit to society by ensuring patient access to quality, safe and 
effective medicines.  
. Any medicines policy must take into account the need to have an environment 
which supports the research and development of innovative medicines, which are 
essential for patients as well as for the sustainability and general equilibrium of 
the medicines market.  
the promotion of competition.13 A study 
which analysed the policy environment 
surrounding the retail market of generic 
medicines in 11 European Union countries 
concluded that if the 10 most commonly 
prescribed and used medicines were 
replaced by generic medicines, government 
spending on medicines could be reduced by 
between 27% and 8%.18 In the EU, the rate 
of spending on medicines is growing faster 
than the economies and thus the promotion 
of the use of cheaper alternatives would 
help governments contain drug expenditure. 
Cheaper alternatives are a result of the price 
competition induced by safe, effective, high 
quality generic medicines. The latter also 
provide an incentive for the development of 
innovative medicines and a reduction in the 
prices of the originator brands.19  
Products which are still patented are 
affected by price competition, as most 
often the drug whose patent has expired 
would be a therapeutic alternative for still 
patented drugs.  Thus, the effects of generic 
substitution are not limited to the generics 
market. It also affects the competition 
in an entire therapeutic area. Generic 
substitution can thus reach its full benefits 
within an efficient marketplace where there 
is free competition.20  
The uptake of generics can be 
stimulated effectively by efficient and fast 
regulatory procedures, legislation, generic 
substitution, information campaigns, 
reference-pricing systems, reimbursement 
systems and prescribing budgets. These 
same instruments must be also effective 
in stimulating competition between 
different brands, so as to ensure long-term 
sustainability of the medicines industry.10 
The latter also depends on the creation 
of an environment that encourages 
pharmaceutical innovation and fosters the 
research-based development of new and 
better medicines.21 
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